Overview
BYSI market data
Price History
BYSI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.02 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,750.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.73 – $2.44 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $37.5M · P/B 6.65 · P/S 27.79.
Company News
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoYBenzinga · Aug 14, 2026, 9:21 PM
8-K filing — BeyondSpring Inc. (BYSI)SEC EDGAR · Aug 14, 2026, 9:15 PM
12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · Aug 14, 2026, 12:06 PM
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 14, 2026, 8:37 AM
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.Benzinga · Aug 13, 2026, 6:29 PM
BeyondSpring's Subsidiary SEED Therapeutics Has Received FDA Orphan Drug Designation For ST-01156 For Treatment Of NeuroblastomaBenzinga · Aug 13, 2026, 3:48 PM
8-K/A filing — BeyondSpring Inc. (BYSI)SEC EDGAR · Jun 29, 2026, 8:30 PM
BeyondSpring Appoints Min Qiu As CEO, Effective July 1Benzinga · Jun 4, 2026, 11:15 AM
Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical BenefitBenzinga · Jun 2, 2026, 11:15 AM